BIGART 2019 – adapting to the future

References

• Grau C, Høyer M, Lindegaard J, et al. The emerging evidence for stereotactic body radiotherapy. Acta Oncol. 2006;45:771–774.
   PubMed Web of Science ®Google Scholar
• Grau C, Muren LP, Høyer M, et al. Image-guided adaptive radiotherapy – integration of biology and technology to improve clinical outcome. Acta Oncol. 2008;47:1182–1185.
   PubMed Web of Science ®Google Scholar
• Grau C, Olsen DR, Overgaard J, et al. Biology-guided adaptive radiation therapy – presence or future? Acta Oncol. 2010;49:884–887.
   PubMed Web of Science ®Google Scholar
• Grau C, Høyer M, Alber M, et al. Biology-guided adaptive radiotherapy (BiGART) – more than a vision? Acta Oncol. 2013;52:1243–1247.
   PubMed Web of Science ®Google Scholar
• Grau C, Overgaard J, Høyer M, et al. Biology-guided adaptive radiotherapy (BiGART) is progressing towards clinical reality. Acta Oncol. 2015;54:1245–1250.
   PubMed Web of Science ®Google Scholar
• Grau C, Høyer M, Poulsen PR, et al. Rethink radiotherapy – BIGART 2017. Acta Oncol. 2017;56:1341–1352.
   PubMed Web of Science ®Google Scholar
• Lievens Y. Access to innovative radiotherapy: how to make it happen from an economic perspective? Acta Oncol. 2017;56:1353–1358.
   PubMed Web of Science ®Google Scholar
• Karsch L, Beyreuther E, Enghardt W, et al. Towards ion beam therapy based on laser plasma accelerators. Acta Oncol. 2017;56:1359–1366.
   PubMed Web of Science ®Google Scholar
• Mohan R, Peeler CR, Guan F, et al. Radiobiological issues in proton therapy. Acta Oncol. 2017;56:1367–1373.
   PubMed Web of Science ®Google Scholar
• Jones B. Clinical radiobiology of proton therapy: modeling of RBE. Acta Oncol. 2017;56:1374–1378.
   PubMed Web of Science ®Google Scholar
• Paganetti H. Relating the proton relative biological effectiveness to tumor control and normal tissue complication probabilities assuming interpatient variability in α/β. Acta Oncol. 2017;56:1379–1386.
   PubMed Web of Science ®Google Scholar
• Sørensen BS, Bassler N, Nielsen S, et al. Relative biological effectiveness (RBE) and distal edge effects of proton radiation on early damage in vivo. Acta Oncol. 2017;56:1387–1391.
   PubMed Web of Science ®Google Scholar
• Lühr A, von Neubeck C, Helmbrecht S, et al. Modeling in vivo relative biological effectiveness in particle therapy for clinically relevant endpoints. Acta Oncol. 2017;56:1392–1398.
   PubMed Web of Science ®Google Scholar
• Müller J, Neubert C, von Neubeck C, et al. Proton radiography for inline treatment planning and positioning verification of small animals. Acta Oncol. 2017;56:1399–1405.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Bassler N, Grzanka L, et al. Differential gene expression in primary fibroblasts induced by proton and cobalt-60 beam irradiation. Acta Oncol. 2017;56:1406–1412.
   PubMed Web of Science ®Google Scholar
• Pedersen J, Petersen JBB, Stokkevåg CH, et al. Biological dose and complication probabilities for the rectum and bladder based on linear energy transfer distributions in spot scanning proton therapy of prostate cancer. Acta Oncol. 2017;56:1413–1419.
   PubMed Web of Science ®Google Scholar
• Ulrich S, Wieser HP, Cao W, et al. Impact of respiratory motion on variable relative biological effectiveness in 4D-dose distributions of proton therapy. Acta Oncol. 2017;56:1420–1427.
   PubMed Web of Science ®Google Scholar
• Ödén J, Toma-Dasu I, Eriksson K, et al. The influence of breathing motion and a variable relative biological effectiveness in proton therapy of left-sided breast cancer. Acta Oncol. 2017;56:1428–1436.
   PubMed Web of Science ®Google Scholar
• Henry T, Bassler N, Ureba A, et al. Development of an interlaced-crossfiring geometry for proton grid therapy. Acta Oncol. 2017;56:1437–1443.
   PubMed Web of Science ®Google Scholar
• Bijman RG, Breedveld S, Arts T, et al. Impact of model and dose uncertainty on model-based selection of oropharyngeal cancer patients for proton therapy. Acta Oncol. 2017;56:1444–1450.
   PubMed Web of Science ®Google Scholar
• Handrack J, Tessonnier T, Chen W, et al. Sensitivity of post treatment positron emission tomography/computed tomography to detect inter-fractional range variations in scanned ion beam therapy. Acta Oncol. 2017;56:1451–1458.
   PubMed Web of Science ®Google Scholar
• de Jong EEC, van Elmpt W, Hoekstra OS, et al. Quality assessment of positron emission tomography scans: recommendations for future multicentre trials. Acta Oncol. 2017;56:1459–1464.
   PubMed Web of Science ®Google Scholar
• Michalak G, Taasti V, Krauss B, et al. A comparison of relative proton stopping power measurements across patient size using dual- and single-energy CT. Acta Oncol. 2017;56:1465–1471.
   PubMed Web of Science ®Google Scholar
• Berger T, Petersen JBB, Lindegaard JC, et al. Impact of bowel gas and body outline variations on total accumulated dose with intensity-modulated proton therapy in locally advanced cervical cancer patients. Acta Oncol. 2017;56:1472–1478.
   PubMed Web of Science ®Google Scholar
• Lindegaard JC, Assenholt M, Ramlov A, et al. Early clinical outcome of coverage probability based treatment planning for simultaneous integrated boost of nodes in locally advanced cervical cancer. Acta Oncol. 2017;56:1479–1486.
   PubMed Web of Science ®Google Scholar
• Zegers CML, Baeza JA, van Elmpt W, et al. Three-dimensional dose evaluation in breast cancer patients to define decision criteria for adaptive radiotherapy. Acta Oncol. 2017;56:1487–1494.
   PubMed Web of Science ®Google Scholar
• Hansen CR, Nielsen M, Bertelsen AS, et al. Automatic treatment planning facilitates fast generation of high-quality treatment plans for esophageal cancer. Acta Oncol. 2017;56:1495–1500.
   PubMed Web of Science ®Google Scholar
• Stuyck C, Wegge M, Bulens P, et al. Moderate dose escalation with volumetric modulated arc therapy improves outcome in rectal cancer. Acta Oncol. 2017;56:1501–1506.
   PubMed Web of Science ®Google Scholar
• Casares-Magaz O, Muren LP, Moiseenko V, et al. Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer. Acta Oncol. 2017;56:1507–1513.
   PubMed Web of Science ®Google Scholar
• Schack LMH, Petersen SE, Nielsen S, et al. Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. Acta Oncol. 2017;56:1514–1521.
   PubMed Web of Science ®Google Scholar
• Schernberg A, Blanchard P, Chargari C, et al. Neutrophils, a candidate biomarker and target for radiation therapy? Acta Oncol. 2017;56:1522–1530.
   PubMed Web of Science ®Google Scholar
• Bogowicz M, Riesterer O, Stark LS, et al. Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma. Acta Oncol. 2017;56:1531–1536.
   PubMed Web of Science ®Google Scholar
• van Timmeren JE, Leijenaar RTH, van Elmpt W, et al. Feature selection methodology for longitudinal cone-beam CT radiomics. Acta Oncol. 2017;56:1537–1543.
   PubMed Web of Science ®Google Scholar
• Larue R, van Timmeren JE, de Jong EEC, et al. Influence of gray level discretization on radiomic feature stability for different CT scanners, tube currents and slice thicknesses: a comprehensive phantom study. Acta Oncol. 2017;56:1544–1553.
   PubMed Web of Science ®Google Scholar
• Zukauskaite R, Hansen CR, Brink C, et al. Analysis of CT-verified loco-regional recurrences after definitive IMRT for HNSCC using site of origin estimation methods. Acta Oncol. 2017;56:1554–1561.
   PubMed Web of Science ®Google Scholar
• Rasmussen GB, Håkansson KE, Vogelius IR, et al. Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. Acta Oncol. 2017;56:1562–1570.
   PubMed Web of Science ®Google Scholar
• Boeke S, Thorwarth D, Mönnich D, et al. Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. Acta Oncol. 2017;56:1571–1576.
   PubMed Web of Science ®Google Scholar
• Mönnich D, Thorwarth D, Leibfarth S, et al. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer. Acta Oncol. 2017;56:1577–1582.
   PubMed Web of Science ®Google Scholar
• Busk M, Munk OL, Jakobsen SS, et al. Hypoxia positron emission tomography imaging: combining information on perfusion and tracer retention to improve hypoxia specificity. Acta Oncol. 2017;56:1583–1590.
   PubMed Web of Science ®Google Scholar
• Even AJG, Reymen B, La Fontaine MD, et al. Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT. Acta Oncol. 2017;56:1591–1596.
   PubMed Web of Science ®Google Scholar
• Abravan A, Knudtsen IS, Eide HA, et al. A new method to assess pulmonary changes using 18F-fluoro-2-deoxyglucose positron emission tomography for lung cancer patients following radiotherapy. Acta Oncol. 2017;56:1597–1603.
   PubMed Web of Science ®Google Scholar
• Sloth Møller D, Knap MM, Nyeng TB, et al. Difference in target definition using three different methods to include respiratory motion in radiotherapy of lung cancer. Acta Oncol. 2017;56:1604–1609.
   PubMed Web of Science ®Google Scholar
• De Ruysscher D, Lambrecht M, van Baardwijk A, et al. Standard of care in high-dose radiotherapy for localized non-small cell lung cancer. Acta Oncol. 2017;56:1610–1613.
   PubMed Web of Science ®Google Scholar
• Fode MM, Bak-Fredslund K, Petersen JB, et al. A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[(18)F]fluoro-2-deoxy-d-galactose. Acta Oncol. 2017;56:1614–1620.
   PubMed Web of Science ®Google Scholar
• Lancia A, Ingrosso G, Carosi A, et al. Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis. Acta Oncol. 2017;56:1621–1625.
   PubMed Web of Science ®Google Scholar
• Iversen AB, Busk M, Bertelsen LB, et al. The potential of hyperpolarized 13C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agents. Acta Oncol. 2017;56:1626–1633.
   PubMed Web of Science ®Google Scholar
• Horsman MR. Enhancing the radiation response of tumors but not early or late responding normal tissues using a vascular disrupting agent. Acta Oncol. 2017;56:1634–1638.
   PubMed Web of Science ®Google Scholar
• Jensen MB, Guldberg TL, Harbøll A, et al. Diffusion tensor magnetic resonance imaging driven growth modeling for radiotherapy target definition in glioblastoma. Acta Oncol. 2017;56:1639–1643.
   PubMed Web of Science ®Google Scholar
• Laurberg T, Overgaard J. Intrinsic subtype characterization of local recurrences and new contralateral primary tumors in patients with low risk breast cancer. Influence of age and primary surgery. Acta Oncol. 2017;56:1644–1647.
   PubMed Web of Science ®Google Scholar
• Lakosi F, Antal G, Pall J, et al. Clinical outcome in prostate cancer treated with magnetic resonance imaging-guided high-dose-rate brachytherapy combined with external beam radiotherapy. Acta Oncol. 2017;56:1647–1651.
   PubMed Web of Science ®Google Scholar
• Mahmood F, Johannesen HH, Geertsen P, et al. Ultra-early apparent diffusion coefficient change indicates irradiation and predicts radiotherapy outcome in brain metastases. Acta Oncol. 2017;56:1651–1653.
   PubMed Web of Science ®Google Scholar
• Milo MLH, Spejlborg H, Thorsen LBJ, et al. Pectus excavatum and adjuvant radiotherapy for early stage breast cancer: balancing dose to target versus heart. Acta Oncol. 2017;56:1653–1656.
   PubMed Web of Science ®Google Scholar
• Berkovic P, Paelinck L, Gulyban A, et al. Adaptive radiotherapy for locally advanced non-small cell lung cancer: dosimetric gain and treatment outcome prediction. Acta Oncol. 2017;56:1656–1659.
   PubMed Web of Science ®Google Scholar
• Winter RM, Schmidt H, Leibfarth S, et al. Distortion correction of diffusion-weighted magnetic resonance imaging of the head and neck in radiotherapy position. Acta Oncol. 2017;56:1659–1663.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Lewison G, Rodin D, et al. Radiation therapy research: a global analysis 2001–2015. Int J Radiat Oncol Biol Phys. 2018;101:767–778.
   PubMed Web of Science ®Google Scholar
• Taasti VT, Jeong J, Jackson A, et al. A theoretical investigation of adequate range uncertainty margins in proton treatment planning to preserve tumor control probability. Acta Oncol. 2019;58:1446–1450.
   PubMed Web of Science ®Google Scholar
• Nenoff L, Matter M, Hedlund Lindmar J, et al. Daily adaptive proton therapy – the key to innovative planning approaches for paranasal cancer treatments. Acta Oncol. 2019;58:1423–1428.
   PubMed Web of Science ®Google Scholar
• Stokkevåg CH, Indelicato DJ, Herfarth K, et al. Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy. Acta Oncol. 2019;58:1416–1422.
   PubMed Web of Science ®Google Scholar
• Toussaint L, Indelicato DJ, Holgersen KS, et al. Towards proton arc therapy: physical and biologically equivalent doses with increasing number of beams in pediatric brain irradiation. Acta Oncol. 2019;58:1451–1456.
   PubMed Web of Science ®Google Scholar
• Neppl S, Landry G, Kurz C, et al. Evaluation of proton and photon dose distributions recalculated on 2D and 3D Unet-generated pseudoCTs from T1-weighted MR head scans. Acta Oncol. 2019;58:1429–1434.
   PubMed Web of Science ®Google Scholar
• van de Water S, Safai S, Schippers JM, et al. Towards FLASH proton therapy: the impact of treatment planning and machine characteristics on achievable dose rates. Acta Oncol. 2019;58:1463–1469.
   PubMed Web of Science ®Google Scholar
• Bourhis J, Montay-Gruel P, Gonçalves Jorge P, et al. Clinical translation of FLASH radiotherapy: why and how? Radiother Oncol. 2019;139:11–17.
   PubMed Web of Science ®Google Scholar
• Maxim PG, Keall P, Cai J. FLASH radiotherapy: newsflash or flash in the pan? Med Phys. 2019; DOI:10.1002/mp.13685.
   PubMed Web of Science ®Google Scholar
• Harrington KJ. Ultrahigh dose-rate radiotherapy: next steps for FLASH-RT. Clin Cancer Res. 2019;25:3–5.
   PubMed Web of Science ®Google Scholar
• Montay-Gruel P, Acharya MM, Petersson K, et al. Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species. Proc Natl Acad Sci USA. 2019;116:10943–10951.
   PubMed Web of Science ®Google Scholar
• Weber DC, Grau C, Lim PS, et al. Bringing Europe together in building clinical evidence for proton therapy – the EPTN-ESTRO-EORTC endeavor. Acta Oncol. 2019;58:1340–1342.
   PubMed Web of Science ®Google Scholar
• Casares-Magaz O, Bülow S, Pettersson NJ, et al. High accumulated doses to the inferior rectum are associated with late gastro-intestinal toxicity in a case-control study of prostate cancer patients treated with radiotherapy. Acta Oncol. 2019;58:1543–1546.
   PubMed Web of Science ®Google Scholar
• Aarup-Kristensen S, Hansen CR, Forner L, et al. Osteoradionecrosis of the mandible after radiotherapy for head and neck cancer: risk factors and dose-volume correlations. Acta Oncol. 2019;58:1373–1377.
   PubMed Web of Science ®Google Scholar
• Farr KP, Khalil AA, Grau C. Patient-reported lung symptoms and quality of life before and after radiation therapy for non-small cell lung cancer: correlation with radiation pneumonitis and functional imaging. Acta Oncol. 2019;58:1523–1527.
   PubMed Web of Science ®Google Scholar
• Eulitz J, Troost EGC, Raschke F, et al. Predicting late magnetic resonance image changes in glioma patients after proton therapy. Acta Oncol. 2019;58:1536–1539.
   PubMed Web of Science ®Google Scholar
• Kaae JK, Johnsen L, Hansen CR, et al. Relationship between patient and physician-rated xerostomia and dose distribution to the oral cavity and salivary glands for head and neck cancer patients after radiotherapy. Acta Oncol. 2019;58:1366–1372.
   PubMed Web of Science ®Google Scholar
• Hansen CR, Friborg J, Jensen K, et al. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy. Acta Oncol. 2019;58:1410–1415.
   PubMed Web of Science ®Google Scholar
• Evensen JF, Sand Hansen H, Overgaard M, et al. DAHANCA 9 – a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). Acta Oncol. 2019;58:1502–1505.
   PubMed Web of Science ®Google Scholar
• Witlox WJA, Ramaekers BLT, Groen HJM, et al. Factors determining the effect of prophylactic cranial irradiation (PCI) in patients with stage-III nonsmall cell lung cancer: exploratory subgroup analyses of the NVALT-11/DLCRG-02 phase-III study. Acta Oncol. 2019;58:1528–1531.
   PubMed Web of Science ®Google Scholar
• Blanchard P, Aupérin A, Pignon J-P. Are Individual patient data meta-analyses still needed today in oncology? A discussion focused on Head & Neck oncology. Acta Oncol. 2019;58:1333–1336.
   Google Scholar
• Jørgensen N, Meline EL, Jeppesen SS, et al. The effect of tumor laterality on survival for non-small cell lung cancer patients treated with radiotherapy. Acta Oncol. 2019;58:1393–1398.
   PubMed Web of Science ®Google Scholar
• Pouymayou B, Koechli C, Balermpas P, et al. Analysis of lymphatic metastasis and progression patterns for clinical target volume (CTV) definition in head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2019;58:1519–1522.
   PubMed Web of Science ®Google Scholar
• Hansen O, Kristiansen C, Nielsen M, et al. Survival after stereotactic radiotherapy in patients with early-stage non-small cell lung cancer. Acta Oncol. 2019;58:1399–1403.
   PubMed Web of Science ®Google Scholar
• Lacoppidan T, Vogelius IR, Pøhl M, et al. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer. Acta Oncol. 2019;58:1386–1392.
   PubMed Web of Science ®Google Scholar
• Lilja-Fischer JK, Saksø M, Stougaard M, et al. Distinguishing recurrence and new primary tumor as well as the origin of neck metastases in head and neck cancer clinical trials by targeted DNA sequencing. Acta Oncol. 2019;58:1506–1508.
   PubMed Web of Science ®Google Scholar
• Hill-Madsen L, Kristensen CA, Andersen E, et al. Subglottic squamous cell carcinoma in Denmark 1971–2015 – a national population-based cohort study from DAHANCA, the Danish Head and Neck Cancer group. Acta Oncol. 2019;58:1509–1513.
   PubMed Web of Science ®Google Scholar
• Bogowicz M, Tanadini-Lang S, Veit-Haibach P, et al. Perfusion CT radiomics as potential prognostic biomarker in head and neck squamous cell carcinoma. Acta Oncol. 2019;58:1514–1518.
   PubMed Web of Science ®Google Scholar
• Lilja-Fischer JK, Ulhøi BP, Alsner J, et al. Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts. Acta Oncol. 2019;58:1489–1494.
   Google Scholar
• Saksø M, Andersen E, Bentzen J, et al. A prospective, multi-center DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. Acta Oncol. 2019;58:1495–1501.
   Google Scholar
• Nielsen M, Kristiansen C, Schytte T, et al. Initial experiences with hippocampus-sparing whole-brain radiotherapy for lung cancer patients. Acta Oncol. 2019;58:1540–1542.
   PubMed Web of Science ®Google Scholar
• Trip AK, Jensen MB, Kallehauge JF, et al. Individualizing the radiotherapy target volume for glioblastoma using DTI-MRI: a phase 0 study on coverage of recurrences. Acta Oncol. 2019;58:1532–1535.
   PubMed Web of Science ®Google Scholar
• Apolle R, Appold S, Bijl HP, et al. Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. Acta Oncol. 2019;58:1378–1385.
   PubMed Web of Science ®Google Scholar
• Jagt TZ, Breedveld S, van Haveren R, et al. Plan-library supported automated replanning for online-adaptive intensity-modulated proton therapy of cervical cancer. Acta Oncol. 2019;58:1440–1445.
   PubMed Web of Science ®Google Scholar
• Busk M, Horsman MR, Overgaard J, et al. Dual-tracer PET of viable tumor volume and hypoxia for identification of necrosis-containing radio-resistant sub-volumes. Acta Oncol. 2019;58:1476–1482.
   PubMed Web of Science ®Google Scholar
• Lise B Bentzen L, Keiding S, Horsman MR, et al. Tumour oxygenation assessed by [18F]fluoro-misonidazole PET and polarographic needle electrodes in human soft tissue sarcomas. Radiother Oncol. 2003;67:339–344.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Mortensen LS, Petersen J, et al. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9:674–687.
   PubMed Web of Science ®Google Scholar
• Skaarup M, Edmund JM, Dorn S, et al. Dual-energy material decomposition for cone-beam computed tomography in image-guided radiotherapy. Acta Oncol. 2019;58:1483–1488.
   PubMed Web of Science ®Google Scholar
• Matter M, Nenoff L, Meier G, et al. Intensity modulated proton therapy plan generation in under ten seconds. Acta Oncol. 2019;58:1435–1439.
   PubMed Web of Science ®Google Scholar
• Minsky BD. Emerging trends in the treatment of rectal cancer. Acta Oncol. 2019;58:1343–1351.
   PubMed Web of Science ®Google Scholar
• Lievens Y, Grau C, Aggarwal A. Value-based health care – what does it mean for radiotherapy? Acta Oncol. 2019;58:1328–1332.
   PubMed Web of Science ®Google Scholar
• Thomas M, Borggreve AS, van Rossum PSN, et al. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis. Acta Oncol. 2019;58:1358–1365.
   Google Scholar
• Stjernswärd J. Decreased survival related to irradiation postoperatively in early operable breast cancer. Lancet. 1974;2:1285–1286.
   PubMed Web of Science ®Google Scholar
• Stjernsward J. Can survival be decreased by post-operative irradiation. Int J Radiat Oncol Biol Phys. 1977;2:1171–1175.
   PubMed Web of Science ®Google Scholar
• Bertelsen AS, Schytte T, Møller PK, et al. First clinical experiences with a high field 1.5 T MR linac. Acta Oncol. 2019;58:1352–1357.
   PubMed Web of Science ®Google Scholar